首頁 > 市場調查報告書 > 製藥

感染疾病

市場調查報告書

商品編碼

1566194

HIV 藥物市場規模、佔有率、成長分析，按藥物類別、分銷管道、地區分類 - 產業預測，2024-2031 年

HIV Drugs Market Size, Share, Growth Analysis, By Medication Class (Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors), By Distribution Channel (Hospital Pharmacies, Hospital Pharmacies), By Region - Industry Forecast 2024-2031

出版日期: 2024年10月03日 | 出版商:

SkyQuest | 英文 219 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

2022年全球愛滋病藥物市場規模為316億美元，從2023年的345.7億美元成長到2031年的709.3億美元，在預測期內（2024-2031年）預計複合年成長率為9.4%。

HIV膠囊市場是製藥業的重要組成部分，為愛滋病毒/愛滋病患者提供挽救生命的治療。近年來，由於醫療技術的進步以及對愛滋病毒預防和治療的日益重視，該市場經歷了顯著成長。推動市場擴張的主要因素包括愛滋病毒/愛滋病盛行率的增加、醫療保健服務的改善以及持續的研究和發展。推動市場的主要因素是抗逆轉錄病毒療法（ART）的需求，它仍然是愛滋病毒/愛滋病的標準治療方法。 ART 有效降低病毒量，增強免疫功能，有助於預防病毒傳播。展望2022年和2023年，受多種因素影響，市場預計將持續呈上升趨勢。愛滋病毒/愛滋病患者數量的增加，特別是在新興國家，預計將推動愛滋病毒藥物的需求。此外，持續研究和開發更有效的新藥物，包括長效注射治療的進展，預計也將塑造市場。儘管 COVID-19 大流行擾亂了供應鏈和醫療保健系統，但我們正在努力確保愛滋病毒治療和預防服務的連續性，並幫助減輕對愛滋病毒藥物市場的影響。

市場概況
多重藥物合併用藥
- 阿特里普拉
- 康普雷拉
- 普雷茲科維克斯
- 斯特里構建
- 玄博屋
- 奧德布塞
- 辛圖札
- 特里梅克
- 德斯科比
- 多瓦托
- 其他
核苷逆轉錄酶抑制劑（NRTI）
- 姆特里巴
- 依匹韋
- Epzicom/Kibexa
- 特魯巴達
- 勝利
- 其他
非核苷類逆轉錄酶抑制劑（NNRTI）
- 教育者
- 其他
蛋白酶抑制劑 (PI)
- 阿普蒂總線
- 克力芝
- 萊克西瓦/泰爾齊爾
- 諾維爾
- 維拉西普
- 其他
侵襲抑制劑
- 塞爾岑特里
- 融合
- 盧科維亞
HIV整合酶鏈轉移抑制劑
- Eyesentless/Isentless HD
- 蒂比凱
- 光圈
- 尤爾卡
其他

HIV藥物市場：依分銷管道分類

市場概況
醫院藥房
藥局和藥局零售
網路藥房

HIV 藥物市場：按地區分類的規模

市場概況
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲國家地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 其他亞太地區
拉丁美洲
- 巴西
- 其他拉丁美洲地區
中東和非洲 (MEA)
- 海灣合作理事會國家
- 南非
- 其他中東/非洲地區

競爭格局

前5名企業對比
主要企業市場定位（2023年）
主要市場參與者所採取的策略
近期市集活動
主要企業市場佔有率（2023年）

主要企業簡介

Gilead Sciences, Inc.（US）
AbbVie Inc.（US）
Bristol-Myers Squibb Company（US）
Johnson & Johnson（US）
GlaxoSmithKline plc（UK）
Teva Pharmaceutical Industries Ltd.（Israel）
F. Hoffmann-La Roche Ltd.（Switzerland）
Merck & Co., Inc.（US）
Boehringer Ingelheim International GmbH（Germany）
Cipla Ltd.（India）
ViiV Healthcare（UK）
AstraZeneca plc（UK）
Hikma Pharmaceuticals PLC（UK）
Abbott Laboratories（US）
Eli Lilly and Company（US）
Alvogen（US）
Aurobindo Pharma（India）
Mundipharma（Switzerland）
Sanofi SA（France）
Novartis AG（Switzerland）
Dr. Reddy's Laboratories（India）
Zydus Cadila（India）
Perrigo Company plc（Ireland）

簡介目錄

Product Code: SQMIG35I2310

Global HIV Drugs Market size was valued at USD 31.6 billion in 2022 and is poised to grow from USD 34.57 billion in 2023 to USD 70.93 billion by 2031, growing at a CAGR of 9.4% during the forecast period (2024-2031).

The HIV capsules market is a vital sector within the pharmaceutical industry, providing life-saving treatments for individuals living with HIV/AIDS. This market has experienced considerable growth in recent years due to advancements in medical technology and a heightened emphasis on HIV prevention and treatment. Key drivers of market expansion include the increasing prevalence of HIV/AIDS, improved access to healthcare services, and ongoing research and development efforts. The primary factor propelling the market is the demand for antiretroviral therapy (ART), which remains the standard treatment for HIV/AIDS. ART effectively reduces viral load, boosts immune function, and helps prevent virus transmission. Looking ahead to 2022 and 2023, the market is expected to continue its upward trend, influenced by several factors. The rising number of HIV/AIDS cases, especially in developing countries, is anticipated to drive demand for HIV medications. Additionally, ongoing research and the development of new, more effective drugs, including advancements in long-acting injectable treatments, are likely to shape the market. While the COVID-19 pandemic has caused some disruptions in supply chains and healthcare systems, efforts are underway to ensure the continuity of HIV treatment and prevention services, helping to mitigate the impact on the HIV drugs market.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global HIV Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global HIV Drugs Market Segmental Analysis

Global HIV Drugs Market is segmented by Medication Class, Distribution Channel. Based on Medication Class, the market is segmented into Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors (PIs), Entry Inhibitors, HIV Integrase Strand Transfer Inhibitors, and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Drugs stores and retail pharmacies, Online pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Drivers of the Global HIV Drugs Market

The persistently high global prevalence of HIV/AIDS is a major driver for the ongoing demand for antiretroviral medications. Supportive government initiatives, particularly in developing nations, along with international funding programs, play a crucial role in market growth by enhancing accessibility to these vital treatments. The Asia-Pacific region, in particular, is experiencing rapid market growth due to advancements in health awareness, improvements in healthcare infrastructure, and the increasing number of hospitals and ambulatory surgical centers equipped with advanced medical facilities. Ongoing research and development efforts are leading to the discovery of new and more effective antiretroviral drugs, further stimulating market expansion. Increased awareness and proactive testing initiatives are also contributing to early detection and a higher demand for HIV medications. Additionally, global collaborations between governments, non-profit organizations, and pharmaceutical companies aim to address the challenges of HIV/AIDS, supporting market growth and improving treatment outcomes.

Restraints in the Global HIV Drugs Market

Access to HIV medications remains a significant challenge, particularly in developing regions where affordability issues can hinder patients' ability to obtain essential treatments. In addition, stigma associated with HIV/AIDS in various societies can obstruct awareness campaigns, deter testing, and reduce patient adherence to treatment regimens. The presence of generic versions of certain HIV drugs further complicates market dynamics, especially in areas where cost-effectiveness is a critical factor. Additionally, inadequate healthcare infrastructure in many developing countries can impede the efficient distribution and administration of HIV medications, affecting market growth. The emergence of drug-resistant HIV strains also challenges the effectiveness of current antiretroviral treatments, underscoring the need for ongoing research and development to address these evolving issues.

Market Trends of the Global HIV Drugs Market

A notable trend in HIV treatment is the development and adoption of single-tablet regimens that combine multiple antiretroviral medications into one pill. This approach streamlines treatment protocols, enhancing patient adherence and convenience by reducing the complexity of medication schedules. Such single-tablet regimens make managing HIV treatment more straightforward, contributing to better adherence and overall patient satisfaction. By consolidating several medications into one convenient form, these regimens not only simplify the treatment process but also improve the effectiveness of therapy by ensuring consistent medication use.

Introduction

Objectives of the Study
Definitions
Market Scope

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Market Overview Outlook
Supply Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Technology Analysis
Pricing Analysis
Value Chain Analysis
Ecosystem of the Market
Trade Analysis
Supply chain Analysis
Case study Analysis
Patent Analysis
Customer & Buying Criteria Analysis
Regulatory Landscape
Innovation Matrix
Top Investment Analysis
Key Success Factor
Degree of Competition

HIV Drugs Market by Medication Class

Market Overview
Multi-Class Combination Drugs
- Atripla
- Complera
- Prezcobix
- Stribild
- Genvoya
- Odefsey
- Symtuza
- Triumeq
- Descovy
- Dovato
- Others
Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
- Emtriva
- Epivir
- Epzicom/Kivexa
- Truvada
- Biktarvy
- Others
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
- Edurant
- Others
Protease Inhibitors (PIs)
- Aptivus
- Kaletra
- Lexiva/ Telzir
- Norvir
- Viracept
- Others
Entry Inhibitors
- Selzentry
- Fuzeon
- Rukobia
HIV Integrase Strand Transfer Inhibitors
- Isentress/Isentress HD
- Tivicay
- Apretude
- Juluca
Others

HIV Drugs Market by Distribution Channel

Market Overview
Hospital Pharmacies
Drugs stores and retail pharmacies
Online pharmacies

HIV Drugs Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2023
Strategies Adopted by Key Market Players
Recent Activities in the Market
Key Companies Market Share (%), 2023

Key Company Profiles

Gilead Sciences, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AbbVie Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bristol-Myers Squibb Company (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GlaxoSmithKline plc (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Teva Pharmaceutical Industries Ltd. (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
F. Hoffmann-La Roche Ltd. (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co., Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Boehringer Ingelheim International GmbH (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cipla Ltd. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
ViiV Healthcare (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca plc (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Hikma Pharmaceuticals PLC (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Abbott Laboratories (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eli Lilly and Company (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Alvogen (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Aurobindo Pharma (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Mundipharma (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi S.A. (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Dr. Reddy's Laboratories (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Zydus Cadila (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Perrigo Company plc (Ireland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments